<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-113677</identifier>
<setSpec>1699-258X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Increased concentrations of soluble CD40 ligand platelet in patients with primary antiphospholipidic syndrome</dc:title>
<dc:description xml:lang="en">Objective. To determine the concentrations of sCD40L in patients with PAPS, and establish its association with the number of thrombosis. Patients and methods. We included patients with PAPS and healthy controls of the same age and sex. For analysis, patients with PAPS were divided into 2 groups: (1) patients with 1 thrombosis, and (2) patients with &gt;1 thrombosis. Soluble CD40L concentrations were determined by ELISA method. Results. sCD40L concentrations were significantly higher in patients with PAPS compared with the controls (9.72±11.23 ng/ml vs 4.69±4.04 ng/ml) (P=.04) There was no association between serum levels of sCD40L and the number of thrombosis (1 thrombosis: 9.81±9.87 ng/ml vs 9.63±12.75 ng/ml in &amp;#8805;1 thrombosis (P=.13). In women with pregnancy and abortions (13 patients), concentrations of sCD40L were higher than in those patients without a history of abortion (26 patients) but without statically significant difference (12.11±16.46 ng/ml vs 8.80±8.61 ng/ml) (P=.33). There was no correlation between levels of sCD40L and the total number of thrombosis. Conclusions. Patients with PAPS have higher concentrations of sCD40L compared with healthy subjects, although this is not associated with a greater number of thrombosis. Among patients with PAPS, there is a tendency to higher concentrations of sCD40L in women with pregnancy and history of abortion. Since the platelet is the main cellular source of sCD40L, is possible that this pathway plays a pathogenic role in patients with PAPS(AU)</dc:description>
<dc:creator>Olguín Ortega, Lourdes</dc:creator>
<dc:creator>Méndez Cruz, René</dc:creator>
<dc:creator>Galicia López, Aida</dc:creator>
<dc:creator>Saavedra, Miguel A</dc:creator>
<dc:creator>García de la Peña, Maximiliano</dc:creator>
<dc:creator>Jimenez Flores, Rafael</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo. Determinar las concentraciones de sCD40L en pacientes con SAFP, y su asociación con el número de trombosis. Pacientes y métodos. Se incluyó a pacientes con SAFP y controles sanos de la misma edad y sexo. Para su análisis, los pacientes con SAFP se dividieron en 2 grupos: a) pacientes con 1 trombosis, y b) pacientes &gt; 1 trombosis. Se determinaron las concentraciones de sCD40L por método de ELISA en cada uno de ellos. Resultados. Las concentraciones de sCD40L fueron significativamente mayores en los pacientes con SAFP en comparación con el grupo control: 9,72 ± 11,23 ng/ml vs. 4,69 ± 40,04 ng/ml (p = 0,04). No hubo asociación entre las concentraciones séricas de sCD40L y el número de trombosis (9,81 ± 9,67 ng/ml en pacientes con una trombosis vs. 9,6 ± 12,75 ng/ml en &amp;#8805; 1 trombosis) (p = 0,13) En mujeres con embarazo y aborto del primer trimestre (13 pacientes), las concentraciones de sCD40L fueron mayores que en aquellas pacientes sin antecedente de aborto (26 pacientes), pero sin una diferencia estadística significativa (12,11 ± 16,46 ng/ml vs. 8,80 ± 8,61 ng/ml; p = 0,33). No se encontró correlación entre las concentraciones de sCD40L y el número total de trombosis. Conclusiones. Los pacientes con SAFP tienen concentraciones mayores de sCD40L en comparación con sujetos sanos, sin que esto se asocie a un mayor número de trombosis. Entre las pacientes con SAFP, existe una tendencia a mayores concentraciones de sCD40L en aquellas con embarazo e historia de aborto. Al ser la plaqueta la principal fuente celular de sCD40L, es posible que esta vía desempeñe un papel patogénico en la enfermedad(AU)</dc:description>
<dc:source>Reumatol. clín. (Barc.);9(4): 216-220, jul.-ago.2013. tab, ilus</dc:source>
<dc:identifier>ibc-113677</dc:identifier>
<dc:title xml:lang="es">Incremento en las concentraciones de ligando CD40 soluble plaquetario en pacientes con síndrome antifosfolipídico primario</dc:title>
<dc:subject>^d32846</dc:subject>
<dc:subject>^d28620</dc:subject>
<dc:subject>^d50504^s22016</dc:subject>
<dc:subject>^d30833</dc:subject>
<dc:subject>^d22443^s22045</dc:subject>
<dc:subject>^d50504^s22012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d30257^s22016</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d35344^s22002</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:subject>^d35344^s22000</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d24837^s22021</dc:subject>
<dc:subject>^d28596^s22045</dc:subject>
<dc:subject>^d24837^s22031</dc:subject>
<dc:subject>^d23518</dc:subject>
<dc:subject>^d28596^s22074</dc:subject>
<dc:subject>^d14312^s22012</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d35344</dc:subject>
<dc:type>article</dc:type>
<dc:date>201308</dc:date>
</metadata>
</record>
</ibecs-document>
